glp 1 non alcoholic fatty liver hepatic steatosis Pharmacotherapy for Non-alcoholic Disease Associated with Diabetes Mellitus Type 2 Fatty Liver Disease: How GLP-1

Tesamorelin/Ipamorelin : Tesamorelin is a GHRH analogue that has FDA approval for reduction of visceral fat in HIVassociated lipodystrophy, and is being explored more broadly for visceral fat and metabolic changes related to aging

Remarkable, compared to placebo, studies over the last decade have shown GLP-1 RAs to reduce MACE and other adverse cardiovascular events, like HF

But GLP-1 drugs are very expensive, especially in the United States

By maintaining muscle tissue during caloric deficits, this combination helps achieve a more sculpted physique

KroghP.Role of ochratoxin in disease causation.Fd Chem Toxic;1992213 EOF24 EOF 65

45 A similar benefit was shown in analyses by baseline KCCQ-CSS tertiles, BMI, and LVEF subgroups